The Association of Serum Vascular Endothelial Growth Factor and Ferritin in Diabetic Microvascular Disease

Overview

Journal Diabetes Technol Ther

Specialties Endocrinology
Pharmacology

Date 2013 Nov 28

PMID 24279470

Citations 16

Authors

Li Guo

Fang Jiang

Yue-Ting Tang

Meng-Ya Si

Xiao-Yang Jiao

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor (VEGF) is involved in the pathogenesis of diabetic microvascular disease. Most diabetes patients have higher serum levels of ferritin that may participate in diabetic vascular complications through high oxidative stress induced by iron. However, the mechanistic link between ferritin and VEGF is obscure. The study investigated the association of VEGF and ferritin in patients with diabetic microvascular disease.

Patients And Methods: Sixty patients with type 2 diabetes mellitus (T2DM) and 26 healthy individuals were selected in this study. Serum ferritin, VEGF, hematological parameters, and clinical data were assessed in this cohort. The Spearman rank method was used to evaluate the associations among them.

Results: Serum levels of VEGF and ferritin were significantly higher in diabetes patients compared with the controls; levels of both were elevated with development of the disease. There were positive correlations between VEGF and glucose levels and between VEGF and ferritin in diabetes groups, especially in patients with diabetic retinopathy. Positive correlations were also found between VEGF level and the parameters of age, hemoglobin, and albumin in patients with diabetes hypertension.

Conclusions: Our data suggest that high ferritin levels in T2DM are closely related to the development of diabetic vascular complications through interaction with VEGF.

Citing Articles

Serum ferritin level and associated factors among uncontrolled adult type II diabetic follow-up patients: comparative based cross-sectional study.

Bayih A, Dedefo G, Kinde S, Alem M, Negesso A, Baye A BMC Endocr Disord. 2024; 24(1):144.

PMID: 39107753 PMC: 11305036. DOI: 10.1186/s12902-024-01665-7.

Iron accumulation and lipid peroxidation: implication of ferroptosis in diabetic cardiomyopathy.

Yan X, Xie Y, Liu H, Huang M, Yang Z, An D Diabetol Metab Syndr. 2023; 15(1):161.

PMID: 37468902 PMC: 10355091. DOI: 10.1186/s13098-023-01135-5.

Research Progress on Relationship Between Iron Overload and Lower Limb Arterial Disease in Type 2 Diabetes Mellitus.

Wang Z, Fang S, Ding S, Tan Q, Zhang X Diabetes Metab Syndr Obes. 2022; 15:2259-2264.

PMID: 35936055 PMC: 9347475. DOI: 10.2147/DMSO.S366729.

Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum - a systematic review.

Kuo C, Murphy R, Rupenthal I, Mugisho O BMC Ophthalmol. 2022; 22(1):238.

PMID: 35624430 PMC: 9145105. DOI: 10.1186/s12886-022-02439-2.

Bone Morphogenetic Proteins and Diabetic Retinopathy.

Elmasry K, Habib S, Moustafa M, Al-Shabrawey M Biomolecules. 2021; 11(4).

PMID: 33919531 PMC: 8073699. DOI: 10.3390/biom11040593.

References

Wilkinson C, Ferris 3rd F, Klein R, Lee P, Agardh C, Davis M . Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9):1677-82. DOI: 10.1016/S0161-6420(03)00475-5. View

Wang W, Knovich M, Coffman L, Torti F, Torti S . Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010; 1800(8):760-9. PMC: 2893236. DOI: 10.1016/j.bbagen.2010.03.011. View

. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):807-22. View

Simo R, Hernandez C . Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008; 51(9):1574-80. DOI: 10.1007/s00125-008-0989-9. View

Blancher C, Moore J, Talks K, Houlbrook S, Harris A . Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2001; 60(24):7106-13. View

Cardenas A, Toledo C, Oyarzun C, Sepulveda A, Quezada C, Guillen-Gomez E . Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab Invest. 2012; 93(1):135-44. DOI: 10.1038/labinvest.2012.143. View

Cameron N, Cotter M . Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest. 1995; 96(2):1159-63. PMC: 185307. DOI: 10.1172/JCI118104. View

Sullivan J . Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta. 2008; 1790(7):718-23. DOI: 10.1016/j.bbagen.2008.06.005. View

Peyssonnaux C, Nizet V, Johnson R . Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle. 2008; 7(1):28-32. DOI: 10.4161/cc.7.1.5145. View

10.

Zheng H, Cable R, Spencer B, Votto N, Katz S . Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005; 25(8):1577-83. DOI: 10.1161/01.ATV.0000174126.28201.61. View

11.

Valenti L, Fracanzani A, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P . Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007; 102(6):1251-8. DOI: 10.1111/j.1572-0241.2007.01192.x. View

12.

Antonetti D, Barber A, Hollinger L, Wolpert E, Gardner T . Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999; 274(33):23463-7. DOI: 10.1074/jbc.274.33.23463. View

13.

Iwashita N, Uchida T, Choi J, Azuma K, Ogihara T, Ferrara N . Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia. 2006; 50(2):380-9. DOI: 10.1007/s00125-006-0512-0. View

14.

Fernandez-Real J, Arroyo E, Balanca R, Cabrero D, Fernandez-Castaner M, Soler J . Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998; 21(1):62-8. DOI: 10.2337/diacare.21.1.62. View

15.

Dronavalli S, Duka I, Bakris G . The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008; 4(8):444-52. DOI: 10.1038/ncpendmet0894. View

16.

Wackers F, Young L, Inzucchi S, Chyun D, Davey J, Barrett E . Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004; 27(8):1954-61. DOI: 10.2337/diacare.27.8.1954. View

17.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

18.

Costa P, Soares R . Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013; 92(22):1037-45. DOI: 10.1016/j.lfs.2013.04.001. View

19.

Watada H . Role of VEGF-A in pancreatic beta cells. Endocr J. 2010; 57(3):185-91. DOI: 10.1507/endocrj.k09e-035. View

20.

Halliwell B, Gutteridge J . Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990; 186:1-85. DOI: 10.1016/0076-6879(90)86093-b. View